Vaccination at the forefront of the fight against hepatitis B and C

Vaccination is a key intervention for the elimination of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections to fulfil the WHO’s 2030 global elimination goal. Innovations in 2021 promise to curb HBV transmission by reducing mother-to-child transmission and enhancing vaccine immunogenicity...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Sayed, Manal H., Feld, Jordan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Year in Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690566/
https://www.ncbi.nlm.nih.gov/pubmed/34934180
http://dx.doi.org/10.1038/s41575-021-00570-x
_version_ 1784618667372183552
author El-Sayed, Manal H.
Feld, Jordan J.
author_facet El-Sayed, Manal H.
Feld, Jordan J.
author_sort El-Sayed, Manal H.
collection PubMed
description Vaccination is a key intervention for the elimination of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections to fulfil the WHO’s 2030 global elimination goal. Innovations in 2021 promise to curb HBV transmission by reducing mother-to-child transmission and enhancing vaccine immunogenicity in at-risk adult groups. Additionally, an HCV vaccination trial was conducted, and there were also advances in our understanding of the immunology underpinning the lack of protection against HCV reinfection.
format Online
Article
Text
id pubmed-8690566
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86905662021-12-21 Vaccination at the forefront of the fight against hepatitis B and C El-Sayed, Manal H. Feld, Jordan J. Nat Rev Gastroenterol Hepatol Year in Review Vaccination is a key intervention for the elimination of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections to fulfil the WHO’s 2030 global elimination goal. Innovations in 2021 promise to curb HBV transmission by reducing mother-to-child transmission and enhancing vaccine immunogenicity in at-risk adult groups. Additionally, an HCV vaccination trial was conducted, and there were also advances in our understanding of the immunology underpinning the lack of protection against HCV reinfection. Nature Publishing Group UK 2021-12-21 2022 /pmc/articles/PMC8690566/ /pubmed/34934180 http://dx.doi.org/10.1038/s41575-021-00570-x Text en © Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Year in Review
El-Sayed, Manal H.
Feld, Jordan J.
Vaccination at the forefront of the fight against hepatitis B and C
title Vaccination at the forefront of the fight against hepatitis B and C
title_full Vaccination at the forefront of the fight against hepatitis B and C
title_fullStr Vaccination at the forefront of the fight against hepatitis B and C
title_full_unstemmed Vaccination at the forefront of the fight against hepatitis B and C
title_short Vaccination at the forefront of the fight against hepatitis B and C
title_sort vaccination at the forefront of the fight against hepatitis b and c
topic Year in Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690566/
https://www.ncbi.nlm.nih.gov/pubmed/34934180
http://dx.doi.org/10.1038/s41575-021-00570-x
work_keys_str_mv AT elsayedmanalh vaccinationattheforefrontofthefightagainsthepatitisbandc
AT feldjordanj vaccinationattheforefrontofthefightagainsthepatitisbandc

Ejemplares similares